Applications of 7-Chloro-1-Cyclopropyl-6-Fluoro-1,4-Dihydro-4-Oxoquinoline-3-Carboxylic Acid in Industrial Manufacturing

As a core manufacturer of quinolone intermediates, we supply 7-Chloro-1-Cyclopropyl-6-Fluoro-1,4-Dihydro-4-Oxoquinoline-3-Carboxylic Acid for complex industrial sectors requiring strict process control, verified quality, and traceable supply chains. Below, we detail real-world application areas, compliance frameworks, and integration parameters for downstream industries.

1. Active Pharmaceutical Ingredient (API) Synthesis for Fluoroquinolone Antibiotics

This compound plays a key role in the synthesis of third- and fourth-generation fluoroquinolone antibiotic APIs, including ciprofloxacin analogs. Large-volume pharmaceutical manufacturers employ it during the final condensation and cyclization stages. The compound’s purity and particle size selection directly impact reaction yield, impurity profile, and compliance with regulatory submissions. Downstream production lines require validated batch records, in-process controls, and controlled environments to meet regulatory filings in major global markets.

Industry compliance standards

• ICH Q7 Good Manufacturing Practice for APIs
• US FDA 21 CFR Part 211 (Finished Pharmaceuticals)
• European Pharmacopoeia Monograph 9.2.6
• Chinese Pharmacopoeia (CP) 2020, API section

Typical usage ratio

• 0.9 to 1.05 molar equivalents relative to the target API; adjusted per process efficiency assays and impurity management controls

Downstream process integration

• Charged after completion of starting material condensation, preceding carboxyl activation and cyclopropylation
• Integrated in solvent-free or high-purity DMF reaction systems
• Subjected to in-process HPLC and crystallization for purity and polymorph control

Final product types

• Ciprofloxacin hydrochloride API
• Gatifloxacin mesylate API
• Other quinolone antimicrobial active ingredients

2. Veterinary Drug Production: Quinolone-Based Animal Health APIs

The material serves as a principal synthetic precursor in the manufacturing lines of veterinary-grade quinolones, such as enrofloxacin and danofloxacin. Process teams in veterinary API plants adjust the ratio to control cost and ensure conformance to VICH guidelines. Steps include integration with protected solvent systems, impurity control based on target animal species, and specific residue reduction via post-reaction treatments. The supply chain typically requires traceability for GMP audits and global registration, including samples for residue toxicity studies.

Industry compliance standards

• VICH GL34 (Validation of Analytical Methods)
• EU Regulation (EC) No 470/2009 for Veterinary Residues
• OECD Principles of Good Laboratory Practice (GLP) for veterinary agents
• Chinese Ministry of Agriculture Veterinary Drug GMP

Typical usage ratio

• 1.0 mol equivalent per mole of finished API, with minor adjustments made for process yield based on analytical validation results

Downstream process integration

• Introduced at heterocycle coupling stage, following activation of fluorine and cyclopropyl moieties
• Accompanied by batchwise impurity assays and drying to veterinary standard moisture content
• Final batch release includes API stability studies under ICH conditions

Final product types

• Enrofloxacin veterinary API
• Danofloxacin mesylate veterinary API
• Bulk intermediate for veterinary finished formulations

3. Pharmaceutical Intermediate for Contract Manufacturing Organizations (CMOs)

CMOs utilize this substance as a registered intermediate within modular and multi-purpose synthesis suites, commonly for small-batch GMP campaigns in Europe and North America. Detailed batch documentation and reagent traceability underpin project delivery for custom fluoroquinolone development programs. The compound’s compatibility with continuous flow reactors, as well as traditional stirred-tank reactors, enables precise process scaling. Entry and quarantine controls at site reception meet stringent quality checks before formulation into client-specific molecular scaffolds for preclinical and clinical production pipelines.

Industry compliance standards

• EU GMP for Intermediates (EudraLex Volume 4, Part II)
• US FDA Quality Agreements for CMOs
• ISO 9001:2015 Quality Management Systems in pharmaceutical manufacturing
• REACH Regulation (EC) No 1907/2006—Chemical Registration

Typical usage ratio

• 1.0 equivalent; varies to 1.2 if used in excess for critical step yield optimization in custom syntheses

Downstream process integration

• Received and qualified as per inbound testing SOPs
• Employed at oxoquinoline ring closure stage
• Subjected to kinematic control in both batch and flow chemistry assets

Final product types

• Non-compendial quinolone intermediates for pharma clients
• Novel R&D APIs for preclinical studies
• Intermediates for FDA-registered drug candidates

4. Chemical Reference Standard for Analytical Laboratories

Analytical laboratories and pharmaceutical QC units source this compound as a certified reference standard for developing and validating HPLC and GC methods used in finished drug and intermediate release. Stringent documentation controls, including certified batch analysis, ensure accuracy in calibrating equipment, determining impurity content, and verifying trace-level residues. Material sourced for this purpose requires strictly controlled purity, documented stability studies, and COA traceable to batch numbers for both regulatory audits and method reproducibility reviews.

Industry compliance standards

• USP Reference Standards guidelines
• Ph. Eur. 2.2.46 Chromatographic Separation Techniques
• ISO/IEC 17025:2017 for laboratory competence
• WHO Good Laboratory Practice (GLP) guidelines

Typical usage ratio

• Microgram to milligram scale for each calibration set, prepared according to method validation protocols

Downstream process integration

• Prepared in analytical balances and volumetric solutions
• Used for calibration curves, spike and recovery studies, and impurity profiling
• Retained as lot-specific standard across internal and external laboratory systems

Final product types

• Calibrated HPLC/GC testing solutions
• Reference control samples for routine QC of APIs
• Validated impurity standards for pharmaceutical regulatory submissions